...aren’t on that formulary, and other more recently approved therapies haven’t fared well. For example, Egalet... ...its higher-priced opioids. Egalet filed for bankruptcy in 2018. The company re-launched in 2019 as Zyla Life Sciences...
...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet... ...granted another company expires on Oct. 2, 2018. Arymo ER uses Egalet's Guardian abuse-deterrent technology. Egalet... ...Pa. Product: Arymo ER morphine sulfate extended-release (formerly Egalet-001) Business: Neurology
Jaime De Leon
Arymo ER
morphine sulfate extended-release
Egalet...
...On Jan. 18, pain and drug delivery company Egalet Corp. (NASDAQ:EGLT) raised $40 million in the... ...Investors also have a right to receive a 1.5% royalty payment on net sales of Egalet’s... ...approved this month. Morgan Stanley was the placement agent. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa.
Alex Himes
Arymo ER
Egalet...
...aren’t on that formulary, and other more recently approved therapies haven’t fared well. For example, Egalet... ...its higher-priced opioids. Egalet filed for bankruptcy in 2018. The company re-launched in 2019 as Zyla Life Sciences...
...to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Egalet... ...granted another company expires on Oct. 2, 2018. Arymo ER uses Egalet's Guardian abuse-deterrent technology. Egalet... ...Pa. Product: Arymo ER morphine sulfate extended-release (formerly Egalet-001) Business: Neurology
Jaime De Leon
Arymo ER
morphine sulfate extended-release
Egalet...
...On Jan. 18, pain and drug delivery company Egalet Corp. (NASDAQ:EGLT) raised $40 million in the... ...Investors also have a right to receive a 1.5% royalty payment on net sales of Egalet’s... ...approved this month. Morgan Stanley was the placement agent. Egalet Corp. (NASDAQ:EGLT), Wayne, Pa.
Alex Himes
Arymo ER
Egalet...